The single-nucleotide polymorphisms in CHD5 affect the prognosis of patients with hepatocellular carcinoma

Oncotarget. 2017 Dec 26;9(17):13222-13230. doi: 10.18632/oncotarget.23812. eCollection 2018 Mar 2.

Abstract

Previous studies showed that the low expressions of chromodomain-helicase-DNA-binding protein 5 (CHD5) were intensively associated with deteriorative biologic and clinical characteristics as well as outcomes in many tumors. The aim of this study is to determine whether CHD5 single nucleotide polymorphisms (SNPs) contribute to the prognosis of hepatocellular carcima (HCC). The SNPs were selected according to their linkage disequilibrium (LD) in the targeted next-generation sequencing (NGS) and then genotyped with TaqMan probers. We revealed a rare haplotype AG in CHD5 (SNPs: rs12564469-rs9434711) was markedly associated with HCC prognosis. The univariate and multivariate regression analyses revealed the patients with worse overall survival time were those with tumor metastasis and haplotype AG, as well as cirrhosis, poor differentiation and IV-TNM stage. Based on the available public databases, we discovered the significant association between haplotype AG and CHD5 mRNA expressions only existed in Chinese. These data proposed that the potentially genetic haplotype might functionally contribute to HCC prognosis and CHD5 mRNA expressions.

Keywords: chromodomain-helicase-DNA-binding protein 5; hepatocellular carcinoma; linkage disequilibrium; prognosis; single-nucleotide polymorphisms.